Bailey Jr, Donald B. http://orcid.org/0000-0002-0513-9330
Funding for this research was provided by:
National Center for Advancing Translational Sciences (UL1TR002489, 1U01TR001792)
Article History
Accepted: 7 April 2022
First Online: 4 May 2022
Declarations
:
: Preparation of this manuscript was supported in part by the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (Awards # UL1TR002489 and 1U01TR001792), and in part by Fellows discretionary funds provided by RTI International. The opinions expressed are those of the author and do not represent the official position of NCATS, RTI International, or any current or previous funders. No other sources of financial assistance were used to conduct the study described in the manuscript and/or used to assist with the preparation of the manuscript. The open access fee was paid by RTI International.
: Donald B. Bailey Jr discloses no conflicts of interest but reports other current funding to RTI International from The John Merck Fund, the Centers for Disease Control and Prevention, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and Janssen Pharmaceuticals. He reports recent but completed funding to RTI from Orchard Therapeutics, Sarepta Pharmaceuticals, BioMarin, Travere, and the EveryLife Foundation, as well as donated reagents and equipment from Asuragen.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.